Published in Clin Cancer Res on October 01, 2001
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res (2011) 2.25
The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell (2012) 1.98
Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A (2011) 1.97
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology (2006) 1.54
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol (2014) 1.45
Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Res (2017) 1.40
Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res (2015) 1.29
Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol (2015) 1.22
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res (2014) 1.17
Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS One (2008) 1.14
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer (2011) 1.14
Chemoimmunotherapy. Cancer J (2010) 1.13
Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother (2013) 1.11
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol (2015) 1.08
Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J Biol Chem (2013) 1.06
Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med (2012) 1.04
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther (2012) 1.03
Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Elife (2017) 1.02
Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Cancer (2012) 1.01
New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol (2013) 1.01
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol (2010) 1.01
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med (2010) 1.01
Paclitaxel induces apoptosis in human gastric carcinoma cells. World J Gastroenterol (2003) 0.99
The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecol Oncol (2009) 0.99
Particle platforms for cancer immunotherapy. Int J Nanomedicine (2013) 0.93
Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med (2015) 0.92
Chemotherapy and tumor immunity: an unexpected collaboration. Front Biosci (2008) 0.90
Primary effect of chemotherapy on the transcription profile of AIDS-related Kaposi's sarcoma. BMC Cancer (2002) 0.89
Immune approaches to the treatment of breast cancer, around the corner? Breast Cancer Res (2014) 0.85
Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies. Br J Cancer (2012) 0.84
Immunotherapy for urothelial carcinoma: current status and perspectives. Cancers (Basel) (2011) 0.83
Enhancement of T cell recruitment and infiltration into tumours. Clin Exp Immunol (2014) 0.83
Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. Cancer J (2013) 0.82
Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Med (2014) 0.82
Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clin Med Insights Oncol (2016) 0.80
Histopathologic changes following neoadjuvant chemotherapy in various malignancies. Int J Appl Basic Med Res (2012) 0.79
The numbers of FoxP3+ lymphocytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal status. Cancer Invest (2011) 0.79
The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. Clin Exp Immunol (2013) 0.79
nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. Onco Targets Ther (2016) 0.78
Chemotherapy remains an essential element of personalized care for persons with lung cancers. Ann Oncol (2016) 0.77
Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. Ther Adv Med Oncol (2016) 0.77
Registered report: the CD47-signal regulated protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Elife (2015) 0.77
Association between Chemotherapy-Response Assays and Subsets of Tumor-Infiltrating Lymphocytes in Gastric Cancer: A Pilot Study. J Gastric Cancer (2015) 0.76
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. Breast Cancer Res Treat (2017) 0.75
Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. J Immunol Res (2016) 0.75
Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World J Clin Oncol (2016) 0.75
Novel therapeutic strategies for patients with triple-negative breast cancer. Onco Targets Ther (2016) 0.75
Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic. Endocr Relat Cancer (2017) 0.75
Predictive and prognostic significance of CD8(+) tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy. Oncol Lett (2017) 0.75
Conditioning neoadjuvant therapies for improved immunotherapy of cancer. Biochem Pharmacol (2017) 0.75
Male circumcision: an acceptable strategy for HIV prevention in Botswana. Sex Transm Infect (2003) 5.26
Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol (1998) 3.12
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol (2004) 2.95
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (2009) 2.71
The Revival of Organisms Presumably Killed by Phenol. J Bacteriol (1945) 2.58
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol (2000) 2.00
Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development. Ann Oncol (2009) 1.67
Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res (2001) 1.59
Characterization of latent TGF-beta activation by murine peritoneal macrophages. J Immunol (1995) 1.52
Malignant melanoma. Primary surgical management (excision and node dissection) based on pathology and staging. Cancer (1995) 1.44
Stereotaxic aspiration biopsy in the evaluation of mammographically detected clustered microcalcification. Cancer (1998) 1.42
Detection of immunoglobulin gene rearrangement of B cell non-Hodgkin's lymphomas and leukemias in fresh, unfixed and formalin-fixed, paraffin-embedded tissue by polymerase chain reaction. Lab Invest (1993) 1.42
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol (2013) 1.41
A multistate outbreak of Escherichia coli O157:H7 infections linked to alfalfa sprouts grown from contaminated seeds. Emerg Infect Dis (2001) 1.40
Molecular Profiling Using Breast Cancer Subtype to Plan for Breast Reconstruction. Plast Reconstr Surg (2017) 1.39
Fine needle aspiration of primary pleomorphic liposarcoma of the breast. A case report. Acta Cytol (1999) 1.38
Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res (2000) 1.33
Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Int J Tuberc Lung Dis (2009) 1.26
Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol (1994) 1.23
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol (2006) 1.22
Two-stage plans for patient accrual in phase II cancer clinical trials. Cancer Treat Rep (1980) 1.19
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol (2007) 1.14
Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res (1999) 1.12
Complications of level I and II axillary dissection in the treatment of carcinoma of the breast. Ann Surg (1999) 1.11
Histopathologic evaluation of the ethmoid bone in chronic sinusitis. Am J Rhinol (2001) 1.11
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol (2008) 1.07
Malignant melanoma metastatic to the breast: a report of seven cases diagnosed by fine-needle aspiration cytology. Cancer (1998) 1.06
HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol (1998) 1.05
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. Br J Cancer (2012) 1.05
Propionibacterium acnes as the cause of endocarditis in a liver transplant recipient. Clin Infect Dis (2000) 1.05
Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis. Oncogene (1996) 1.05
The toxicity of rubber additives. Findings from a survey of 140 plants in Ohio. Arch Environ Health (1968) 1.03
Peripheral blood mononuclear cell abnormalities and their relationship to clinical course in homosexual men with HIV infection. Clin Immunol Immunopathol (1988) 1.01
Mammotome core biopsy for mammary microcalcification: analysis of 160 biopsies from 142 women with surgical and radiologic followup. Cancer (2001) 1.00
Malignant mesothelioma of the tunica vaginalis testis. J Clin Oncol (1984) 0.99
Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol (1995) 0.98
The occurrence of Salmonellae in house shrews and rats in Ipoh, Malaysia. Southeast Asian J Trop Med Public Health (1984) 0.98
Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol (1996) 0.98
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol (2013) 0.96
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol (2007) 0.95
Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Clin Cancer Res (1997) 0.95
Fine-needle aspiration cytology of Hodgkin disease: a study of 89 cases with emphasis on false-negative cases. Cancer (2001) 0.94
A Bactericidal Detergent for Eating Utensils. J Bacteriol (1946) 0.93
Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs (1994) 0.92
Suramin antiviral therapy in the acquired immunodeficiency syndrome. Clinical, immunological, and virologic results. Ann Intern Med (1986) 0.92
Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res (2010) 0.92
Malignant pleural effusions due to small-cell lung carcinoma: a cytologic and immunocytochemical study. Diagn Cytopathol (2001) 0.92
Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications. Ann Oncol (1994) 0.91
Epstein-Barr-virus-associated lymphoproliferative disease of the lung: CT and histologic findings. Radiology (1998) 0.91
Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol (2014) 0.90
The Reed-Sternberg cells of Hodgkin disease are clonal. Proc Natl Acad Sci U S A (1994) 0.89
Adjunctive hyperbaric oxygen therapy reduces length of hospitalization in thermal burns. J Burn Care Rehabil (1989) 0.89
Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection. J Viral Hepat (2008) 0.88
Survival with regional and distant metastases from cutaneous malignant melanoma. Surg Gynecol Obstet (1991) 0.88
Plasmacytoma of the breast. A report of two cases diagnosed by aspiration biopsy. Acta Cytol (2000) 0.88
Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. Ann Oncol (2008) 0.87
Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst (1992) 0.87
Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res (1998) 0.87
Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. Br J Surg (2008) 0.87
Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone. Ann Oncol (2006) 0.87
Iron-rich foci in chronic viral hepatitis. Hum Pathol (1998) 0.86
Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer (1992) 0.85
Carcinoid syndrome from a tumor of Meckel's diverticulum. Am J Med (1987) 0.85
Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer. Ann Oncol (2012) 0.85
Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer (1997) 0.85
Chromosomal mapping to 15q14 and expression analysis of the human MEIS2 homeobox gene. Mamm Genome (1997) 0.85
Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol (1999) 0.85
Intraperitoneal chemotherapy: technical experience at five institutions. Semin Oncol (1985) 0.85
Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers. Ecancermedicalscience (2008) 0.84
Sporadic paediatric diarrhoeal illness in urban and rural sites in Nyanza Province, Kenya. East Afr Med J (2009) 0.84
Peripheral T-cell lymphoma. Cancer (1989) 0.84
Immunological profile of breast cancer patients in early or advanced disease. Experientia (1979) 0.83
Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone. Ann Oncol (2008) 0.83
MDR1 gene expression in primary and advanced breast cancer. Lab Invest (1999) 0.83
[Cis-diammino-dichloro-platinum therapy of cancers; phase II therapeutic trial]. Nouv Presse Med (1979) 0.83
A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma. Cancer (2001) 0.83
Mucinous cancer of the appendix: challenges in diagnosis and treatment. J Chemother (2007) 0.83
Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int J Radiat Oncol Biol Phys (1997) 0.83
Aspiration biopsy and the clinical management of patients with malignant melanoma and palpable regional lymph nodes. Cancer (2000) 0.82
Multilocular thymic cyst with follicular lymphoid hyperplasia in a male infected with HIV. A case report with fine needle aspiration cytology. Acta Cytol (1999) 0.81
Phase II trial of carboplatin or iproplatin in cervical cancer. Cancer Chemother Pharmacol (1991) 0.81
Invasive carcinoma in clinically suspicious breast masses diagnosed as adenocarcinoma by fine-needle aspiration. Cancer (2000) 0.81
Outbreak of type A botulism and development of a botulism surveillance and antitoxin release system in Argentina. JAMA (1999) 0.81
Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer (1995) 0.81
The incidence of positive margins with breast conserving therapy following mammotome biopsy for microcalcification. J Surg Oncol (2000) 0.81
Use of E-cadherin and CD44 aids in the differentiation between reactive mesothelial cells and carcinoma cells in pelvic washings. Cancer (2000) 0.81
Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor. J Immunother Emphasis Tumor Immunol (1994) 0.81